Worth reading
54Recurring
Scored from 4 of 5 sectionsDirection
—
Direction inferred from the company’s description.Scale
1794
Millions of yenWording
Conditional
How definitive the wording is.This transaction
This tender offerCounterpartyMEDIPAL HOLDINGS CORPORATION
Disclosing companyS.T.CORPORATION
Execution Date / Effective DateSettlement start date: 14 July 2026
Consideration and expenses
Acquisition priceTotal sale proceeds: ¥2,254 million
Type of ConsiderationCash
Tender offer priceSale price per share: ¥6,650
Tender offer periodStart date: Not disclosed; end date: 7 July 2026; number of business days: Not disclosed
Amount of extraordinary income (loss)Gain on sale of investment securities: ¥1,794 million, to be recognized as an extraordinary gain in the fiscal year ending March 2027
Impact on Business Performance
The Company will recognize a ¥1,794 million gain on the sale of investment securities as an extraordinary gain in its non-consolidated and consolidated financial statements for the fiscal year ending March 2027. The impact on the consolidated earnings forecast is currently under review.
| Item | Details |
|---|---|
| Transaction name | This tender offer |
| Counterparty name | MEDIPAL HOLDINGS CORPORATION |
| Name of the Subject Company | PALTAC CORPORATION |
| Acquisition price | Total sale proceeds: ¥2,254 million |
| Type of Consideration | Cash |
| Tender offer price | Sale price per share: ¥6,650 |
| Tender offer period | Start date: Not disclosed; end date: 7 July 2026; number of business days: Not disclosed |
| Number of shares acquired | 339,000 shares; number of voting rights: Not disclosed |
| Amount of extraordinary income (loss) | Gain on sale of investment securities: ¥1,794 million, to be recognized as an extraordinary gain in the fiscal year ending March 2027 |
| Impact on Business Performance | The Company will recognize a ¥1,794 million gain on the sale of investment securities as an extraordinary gain in its non-consolidated and consolidated financial statements for the fiscal year ending March 2027. The impact on the consolidated earnings forecast is currently under review. |
| Execution Date / Effective Date | Settlement start date: 14 July 2026 |
Items this document does not state (21)
Business Description of the Subject CompanyLocation of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceMerger ratio/share exchange ratioMinimum number of shares to be purchasedVoting rights ownership percentageFunding arrangementsGoodwill amountDate of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This disclosure announces the results of the tender offer and the related recognition of an extraordinary gain. No reason for the sale is stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.